- Approval Id
- 0f9b55109fe525ff
- Drug Name
- GRANODEX SOLUTION FOR INJECTION 1MG/ML
- Product Name
- GRANODEX SOLUTION FOR INJECTION 1MG/ML
- Approval Number
- SIN16589P
- Approval Date
- 2022-09-01
- Registrant
- GLORIOUS DEXA SINGAPORE PTE. LTD.
- Licence Holder
- GLORIOUS DEXA SINGAPORE PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- INJECTION, SOLUTION
- Dosage
- **Recommended Dosage:**
_**Cytostatic therapy**_
_Adults_
3 mg granisetron which should be administered either in 15 ml infusion fluid as an intravenous bolus over not less than 30 seconds or diluted in 20 to 50 ml infusion fluid and administered over five minutes.
Prevention:
The majority of patients have required only a single dose of granisetron to control nausea and vomiting over 24 hours. Up to two additional doses of 3 mg granisetron may be administered within a 24-hour period. There is clinical experience in patients receiving daily administration for up to five consecutive days in one course of therapy. Prophylactic administration of granisetron should be completed prior to the start of cytostatic therapy.
Treatment:
The same dose of granisetron should be used for treatment as prevention. Additional doses should be administered at least 10 minutes apart.
Maximum daily dosage:
Up to three doses of 3 mg granisetron may be administered within a 24-hour period. The maximum dose of granisetron to be administered over 24 hours should not exceed 9 mg.
_Concomitant use of dexamethasone_
The efficacy of granisetron may be enhanced by the addition of dexamethasone.
_Elderly_
No special requirements apply to elderly patients.
_Children_
Prevention:
A single dose of 40 mcg/kg body weight (up to 3 mg) should be administered as an intravenous infusion, diluted in 10 to 30 ml infusion fluid and administered over five minutes. Administration should be completed prior to the start of cytostatic therapy.
Treatment:
The same dose of granisetron as above should be used for treatment as prevention.
One additional dose of 40 mcg/kg body weight (up to 3 mg) may be administered within a 24-hour period. This additional dose should be administered at least 10 minutes apart from the initial infusion.
_Patients with renal or hepatic impairment_
No special requirements apply to those patients with renal or hepatic impairment.
_Preparation of infusion_
Granisetron solution for injection or infusions must be prepared at the time of administration and under appropriate aseptic conditions.
Adults:
To prepare a dose of 3 mg, 3 ml is withdrawn from the ampoule and diluted either to 15 ml with 0.9% sodium chloride (for bolus administration) or in a compatible infusion fluid to a total volume of 20 to 50 ml, in any of the following solutions: 0.9% sodium chloride, Ringer’s lactate, 5% dextrose and 20% mannitol solution. The mixtures solutions are stable within 24 hours at temperatures below 30ºC.
Children:
The appropriate dose is diluted with a compatible infusion fluid (as for adults) to a total volume of 10 to 30 ml, in any of the following solutions: 0.9% sodium chloride, Ringer’s lactate, 5% dextrose and 20% mannitol solution. The mixtures solutions are stable within 24 hours at temperatures below 30ºC.
**_Postoperative nausea and vomiting_**
_Adults_
Prevention:
For prevention in adults, a single dose of 1 mg of granisetron should be diluted to 5 ml and administered as a slow intravenous injection (over 30 seconds). Administration should be completed prior to induction of anesthesia.
Treatment:
For the treatment of established postoperative nausea and vomiting in adults, a single dose of 1 mg of granisetron should be diluted to 5 ml and administered by slow intravenous injection (over 30 seconds).
Maximum dose and duration of treatment:
Two doses (2 mg) in one day.
_Preparation of injection_
Adults:
To prepare a dose of 1 mg, 1 ml should be withdrawn from the ampoule and diluted to 5 ml with 0.9% sodium chloride. No other diluents should be used.
Children:
There is no experience in the use of granisetron in the prevention and treatment of postoperative nausea and vomiting in children. Granisetron is not therefore recommended for the treatment of postoperative nausea and vomiting in this age group.
_Elderly patients_
As for adults.
_Renally impaired and hepatically impaired patients_
As for adults.
- Route Of Administration
- INTRAVENOUS
- Indication Info
- **Indications:**
Granisetron is indicated for the prevention or treatment of nausea and vomiting induced by cytostatic therapy and for the prevention and treatment of postoperative nausea and vomiting.
- Contraindications
- **Contraindication:**
Granisetron is contraindicated in patients with known hypersensitivity to granisetron or to any of its excipients.
- Atc Code
- A04AA02
- Atc Item Name
- granisetron
- Pharma Manufacturer Name
- GLORIOUS DEXA SINGAPORE PTE. LTD.
- Company Detail Path
- /organization/2aea0381f6373713/glorious-dexa-singapore-pte-ltd
